(Q48109035)

8 February 2018

title

Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases (English)

1 reference

8 February 2018

1 reference

7

1 reference

8 February 2018

author name string

Martin Majer

1

1 reference

8 February 2018

Randy L Jensen

2

1 reference

8 February 2018

Dennis C Shrieve

3

1 reference

8 February 2018

Gordon A Watson

4

1 reference

8 February 2018

Michael Wang

5

1 reference

8 February 2018

Sancy A Leachman

6

1 reference

8 February 2018

Wolfram E Samlowski

8

1 reference

8 February 2018

language of work or name

English

0 references

publication date

1 September 2007

1 reference

8 February 2018

published in

Cancer

1 reference

8 February 2018

volume

110

1 reference

8 February 2018

issue

6

1 reference

8 February 2018

page(s)

1329-1337

1 reference

8 February 2018

The current causes of death in patients with malignant melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

The Melanoma Epidemic: Res Ipsa Loquitur

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Chemotherapy for metastatic melanoma: time for a change?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Central nervous system metastases in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Long-term survivors after gamma knife radiosurgery for brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Dose conformity of gamma knife radiosurgery and risk factors for complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22905

1 reference

7 January 2021

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Metastatic melanoma: chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Systemic chemotherapy for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22905

7 January 2021

Identifiers

DOI

10.1002/CNCR.22905

1 reference

8 February 2018

1 reference

8 February 2018